Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals develops immune-modulating therapies as a clinical-stage biotechnology company focused on transplant medicine and other life-threatening conditions. Its lead investigational product, tegoprubart, is an anti-CD40L antibody designed to target the CD40 Ligand pathway, with programs and study updates tied to kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis.
Company news commonly covers tegoprubart clinical data, investigator-initiated transplant studies, FDA orphan drug designations, research collaborations, conference presentations and operating results. Updates also address how the company positions CD40L modulation as a non-lymphocyte-depleting immunomodulatory approach for preventing organ rejection and supporting transplanted cell or organ grafts.
Eledon Pharmaceuticals (Nasdaq: ELDN) will present at the Guggenheim Second Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 10:30 a.m. ET (7:30 a.m. PT). David-Alexandre C. Gros, M.D., CEO, will deliver the presentation. A live webcast will be available with a replay posted on the company website under Events for registered users.
Eledon Pharmaceuticals (Nasdaq: ELDN) announced an oral presentation of topline results from the Phase 2 BESTOW trial of tegoprubart for prevention of rejection in kidney transplantation at ASN Kidney Week 2025 in Houston on November 6, 2025.
The presentation by Andrew Adams, M.D., Ph.D. is scheduled for 5:30–5:42 p.m. CT in Grand Ballroom C. A conference call to discuss the results will be held on November 7, 2025 at 8:00 a.m. ET with a live webcast on the company investor site; the webcast will be archived after the call.
Eledon Pharmaceuticals (Nasdaq: ELDN) announced that its President and Chief Scientific Officer, Steve Perrin, Ph.D., will present at the 18th Congress of the International Xenotransplantation Association (IXA) in Geneva, Switzerland. The presentation will take place on October 1, 2025, from 10:30 a.m. to 12:00 p.m. CET during a plenary session focused on immunosuppression and anti-CD154 pathway blockade.
Eledon Pharmaceuticals (NASDAQ:ELDN) announced its upcoming participation in the Cantor Global Healthcare Conference. The company's CEO, David-Alexandre C. Gros, M.D., will engage in a fireside chat on September 5, 2025, at 9:10 a.m. ET.
Investors can register in advance for the webcast, and a replay will be available on the company's website in the Events section after the live session.
Eledon Pharmaceuticals (NASDAQ: ELDN) reported Q2 2025 financial results and clinical progress for its lead drug tegoprubart. The company highlighted positive Phase 1b data in kidney transplant patients, showing a mean 12-month eGFR of approximately 68 mL/min/1.73 m2, significantly better than the historical standard of care (~53 mL/min/1.73 m2).
Key developments include successful treatment of six islet cell transplant recipients at UChicago Medicine, with the first three achieving insulin independence, and a third patient receiving tegoprubart in kidney xenotransplantation at MGH. The company reported $107.6 million in cash as of June 30, 2025, expected to fund operations through 2026, and anticipates Phase 2 BESTOW trial results in kidney transplantation by November 2025.
Eledon Pharmaceuticals (NASDAQ: ELDN) presented updated data from its ongoing Phase 1b trial of tegoprubart for kidney transplant rejection prevention. The trial showed promising results with patients maintaining an average 12-month eGFR of 68 mL/min/1.73 m², significantly higher than the historical standard of care average of 53 mL/min/1.73 m².
The study enrolled 32 patients, with preliminary iBox data suggesting tegoprubart may achieve over 96% predicted 5-year allograft survival rate. The drug demonstrated strong safety profile with no deaths, graft loss, drug-related tremor, or new-onset diabetes. While six rejection episodes occurred, all were successfully treated, with patients remaining on tegoprubart showing superior kidney function recovery compared to those who switched to standard care.
The company expects topline results from its Phase 2 BESTOW trial in November 2025.Eledon Pharmaceuticals (NASDAQ:ELDN) has announced a conference call and webcast scheduled for August 6, 2025, at 4:30 p.m. ET to discuss updated clinical data from their ongoing Phase 1b study of tegoprubart in kidney transplantation.
The presentation will feature data from approximately 30 kidney transplant recipients and will be presented at the World Transplant Congress (WTC) in San Francisco. The study focuses on tegoprubart's potential in preventing rejection in kidney transplant patients.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced upcoming presentations of updated clinical data from its ongoing Phase 1b study of tegoprubart in kidney transplant patients at the World Transplant Congress 2025. The oral presentation, scheduled for August 6, 2025, will feature results from approximately 30 kidney transplant recipients.
The company will also host a satellite symposium on August 3 discussing kidney transplant success metrics, featuring prominent medical faculty. Additionally, new preclinical data on tegoprubart's use in liver transplantation in non-human primates will be presented in a poster session.
Eledon Pharmaceuticals (NASDAQ:ELDN) announced it will host an R&D Day on July 9, 2025 in New York City, starting at 8:30 am ET. The event will showcase the company's lead investigational candidate, tegoprubart, focusing on its clinical development in organ and cell transplantation, including the ongoing Phase 2 BESTOW trial.
The R&D Day will feature presentations from Eledon's executive team and leading transplantation experts from prestigious institutions. Topics will cover unmet needs in solid organ transplantation, clinical endpoint evolution, and strategic opportunities in islet cell transplantation and xenotransplantation. The event will conclude with a Q&A session and will be available via live webcast.
Eledon Pharmaceuticals (NASDAQ: ELDN) reported its Q1 2025 financial results and provided business updates. The company maintains a strong financial position with $124.9 million in cash and equivalents, expected to fund operations through 2026. Key highlights include the ongoing development of tegoprubart, their novel immunosuppression therapy, which was used in a groundbreaking second pig-to-human kidney transplant at Massachusetts General Hospital.
The company anticipates significant milestones in 2025, including topline results from the Phase 2 BESTOW trial in Q4 2025. Financial results show R&D expenses of $13.5 million and a net loss of $6.5 million for Q1 2025. The net loss includes a $10.1 million non-cash gain from warrant liability changes.